FOLFIRI Plus Panitumumab in the Treatment of Wild-Type KRAS and Wild-Type NRAS Metastatic Colorectal Cancer

World Journal of Surgical Oncology - United Kingdom
doi 10.1186/s12957-018-1359-9
Full Text
Abstract

Available in full text

Categories
SurgeryOncology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer

JAMA Oncology
Cancer ResearchOncology
2019English

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- And PIK3CA- Wild-Type Metastatic Colorectal Cancer: The AGITG Randomised Phase II ICECREAM Study

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy

Cancers
Cancer ResearchOncology
2020English

Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study

Clinical Colorectal Cancer
OncologyGastroenterology
2017English

Relationship Between Tumour Response and Tumour-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials

Clinical Colorectal Cancer
OncologyGastroenterology
2019English

Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) Is an Independent Prognostic Marker in Wild-Type KRAS Metastatic Colorectal Cancer After Colorectal Liver Metastasectomy

BMC Cancer
Cancer ResearchOncologyGenetics
2015English

P16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients With Metastatic Colorectal Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2016English

Skin Toxicity and Quality of Life During Treatment With Panitumumab for RAS Wild-Type Metastatic Colorectal Carcinoma: Results From Three Randomised Clinical Trials

Quality of Life Research
EnvironmentalPublic HealthOccupational Health
2016English

PCN70 Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients With Kras Wild-Type Tumours in the United Kingdom

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy